|
1
|
Zembutsu H, Ohnishi Y, Tsunoda T, et al:
Genome-wide cDNA microarray screening to correlate gene expression
profiles with sensitivity of 85 human cancer xenografts to
anticancer drugs. Cancer Res. 62:518–527. 2002.PubMed/NCBI
|
|
2
|
Dan S, Tsunoda T, Kitahara O, et al: An
integrated database of chemosensitivity to 55 anticancer drugs and
gene expression profiles of 39 human cancer cell lines. Cancer Res.
62:1139–1147. 2002.PubMed/NCBI
|
|
3
|
Park JS, Young Yoon S, Kim JM, Yeom YI,
Kim YS and Kim NS: Identification of novel genes associated with
the response to 5-FU treatment in gastric cancer cell lines using a
cDNA microarray. Cancer Lett. 214:19–33. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fukushima M, Fujioka A, Uchida J, Nakagawa
F and Takechi T: Thymidylate synthase (TS) and ribonucleotide
reductase (RNR) may be involved in acquired resistance to
5-fluorouracil (5-FU) in human cancer xenografts in vivo. Eur J
Cancer. 37:1681–1687. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Francia G, Cruz-Munoz W, Man S, Xu P and
Kerbel RS: Mouse models of advanced spontaneous metastasis for
experimental therapeutics. Nat Rev Cancer. 11:135–141. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Paget S: The distribution of secondary
growths in cancer of the breast. Lancet. 133:571–573. 1889.
View Article : Google Scholar
|
|
7
|
Tashiro T, Inaba M, Kobayashi T, et al:
Responsiveness of human lung cancer/nude mouse to antitumor agents
in a model using clinically equivalent doses. Cancer Chemother
Pharmacol. 24:187–192. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Takechi T, Okabe H, Ikeda K, et al:
Correlations between antitumor activities of fluoropyrimidines and
DPD activity in lung tumor xenografts. Oncol Rep. 14:33–39.
2005.PubMed/NCBI
|
|
9
|
Ishikura H, Kondo K, Miyoshi T, Kinoshita
H, Hirose T and Monden Y: Artificial lymphogenous metastatic model
using orthotopic implantation of human lung cancer. Ann Thorac
Surg. 69:1691–1695. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fujino H, Kondo K, Ishikura H, et al:
Matrix metalloproteinase inhibitor MMI-166 inhibits lymphogenous
metastasis in an orthotopically implanted model of lung cancer. Mol
Cancer Ther. 9:1409–1416. 2005. View Article : Google Scholar
|
|
11
|
Kondo K, Fujino H, Miyoshi T, Ishikura H,
Sakiyama S and Monden Y: Orthotopically implanted SCID mouse model
of human lung cancer suitable for investigating metastatic
potential and anticancer drug effects. Oncol Rep. 5:991–999.
2004.
|
|
12
|
Fujino H, Kondo K, Miyoshi T, et al:
Establishment of patient-like SCID mouse model by orthotopically
implanting primary cultured cells from surgically-resected lung
cancer tissues. Oncol Rep. 6:1709–1715. 2003.
|
|
13
|
Chen ZS and Tiwari AK: Multidrug
resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic
diseases. FEBS J. 278:3226–3245. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Borst P, Evers R, Kool M and Wijnholds J:
A family of drug transporters: the multidrug resistance associated
proteins. J Natl Cancer Inst. 92:1295–1302. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Loe DW, Almquist KC, Deeley RG and Cole
SP: Multidrug resistance protein (MRP)-mediated transport of
leukotriene C4 and chemotherapeutic agents in membrane vesicles.
Demonstration of glutathione-dependent vincristine transport. J
Biol Chem. 271:9675–9682. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tiwari AK, Sodani K, Dai CL, Ashby CR Jr
and Chen ZS: Revisiting the ABCs of multidrug resistance in cancer
chemotherapy. Curr Pharm Biotechnol. 12:570–594. 2011. View Article : Google Scholar
|
|
17
|
Loe DW, Deeley RG and Cole SP:
Characterization of vincristine transport by the M(r) 190,000
multidrug resistance protein (MRP): evidence for cotransport with
reduced glutathione. Cancer Res. 58:5130–5136. 1998.PubMed/NCBI
|
|
18
|
Hegedus T, Orfi L, Seprodi A, Varadi A,
Sarkadi B and Keri G: Interaction of tyrosine kinase inhibitors
with the human multidrug transporter proteins, MDR1 and MRP1.
Biochim Biophys Acta. 1587:318–325. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nooter K, Westerman AM, Flens MJ, et al:
Expression of the multidrug resistance-associated protein (MRP)
gene in human cancers. Clin Cancer Res. 1:1301–1310.
1995.PubMed/NCBI
|
|
20
|
Nooter K, Brutel de la Riviere G, Klijn J,
Stoter G and Foekens J: Multidrug resistance protein in recurrent
breast cancer. Lancet. 349:1885–1886. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Deeley RG, Westlake C and Cole SP:
Transmembrane transport of endo- and xenobiotics by mammalian
ATP-binding cassette multidrug resistance proteins. Physiol Rev.
86:849–899. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cui Y, Konig J, Buchholz JK, Spring H,
Leier I and Keppler D: Drug resistance and ATP-dependent conjugate
transport mediated by the apical multidrug resistance protein,
MRP2, permanently expressed in human and canine cells. Mol
Pharmacol. 55:929–937. 1999.PubMed/NCBI
|
|
23
|
Chu XY, Kato Y, Niinuma K, Sudo KI,
Hakusui H and Sugiyama Y: Multispecific organic anion transporter
is responsible for the biliary excretion of the camptothecin
derivative irinotecan and its metabolites in rats. J Pharmacol Exp
Ther. 281:304–314. 1997.PubMed/NCBI
|
|
24
|
Huisman MT, Chhatta AA, van Tellingen O,
Beijnen JH and Schinkel AH: MRP2 (ABCC2) transports taxanes and
confers paclitaxel resistance and both processes are stimulated by
probenecid. Int J Cancer. 116:824–829. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sandusky GE, Mintze KS, Pratt SE and
Dantzig AH: Expression of multidrug resistance-associated protein 2
(MRP2) in normal human tissues and carcinomas using tissue
microarrays. Histopathology. 41:65–74. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
van der Kolk DM, de Vries EG, Koning JA,
van den Berg E, Muller M and Vellenga E: Activity and expression of
the multidrug resistance proteins MRP1 and MRP2 in acute myeloid
leukemia cells, tumor cell lines, and normal hematopoietic
CD34+ peripheral blood cells. Clin Cancer Res.
4:1727–1736. 1998.PubMed/NCBI
|
|
27
|
Korita PV, Wakai T, Shirai Y, et al:
Multidrug resistance associated protein 2 determines the efficacy
of cisplatin in patients with hepatocellular carcinoma. Oncol Rep.
23:965–972. 2010.PubMed/NCBI
|
|
28
|
Nagahara N and Nishino T: Role of amino
acid residues in the active site of rat liver mercaptopyruvate
sulfurtransferase. cDNA cloning, overexpression, and site-directed
mutagenesis. J Biol Chem. 271:27395–27401. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ramasamy S, Singh S, Taniere P, Langman MJ
and Eggo MC: Sulfide-detoxifying enzymes in the human colon are
decreased in cancer and upregulated in differentiation. Am J
Physiol Gastrointest Liver Physiol. 291:G288–G296. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ooyama A, Takechi T, Toda E, et al: Gene
expression analysis using human cancer xenografts to identify novel
predictive marker. Cancer Sci. 97:510–522. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Golub TR, Slonim DK, Tamayo P, et al:
Molecular classification of cancer: class discovery and class
prediction by gene expression monitoring. Science. 286:531–537.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Golub TR: Genome-wide views of cancer. N
Engl J Med. 8:601–602. 2001. View Article : Google Scholar
|
|
33
|
Mayer F, Hartmann JT, von Pawel J, et al:
A phase I study of oral uracil-ftorafur plus folinic acid in
combination with weekly paclitaxel in patients with solid tumors.
Ann Oncol. 5:755–759. 2002. View Article : Google Scholar
|
|
34
|
Nukatsuka M, Fujioka A, Nakagawa F, et al:
Antimetastatic and anticancer activity of S-1, a new oral
dihydropyrimidine-dehydrogenase inhibiting fluoropyrimidine, alone
and in combination with paclitaxel in an orthotopically implanted
human breast cancer model. Int J Oncol. 25:1531–1536.
2004.PubMed/NCBI
|
|
35
|
Kiyohara C and Yoshimasu K: Genetic
polymorphisms in the nucleotide excision repair pathway and lung
cancer risk: a meta-analysis. Int J Med Sci. 4:59–71. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ott K, Rachakonda PS, Panzram B, et al:
DNA repair gene and MTHFR gene polymorphisms as prognostic markers
in locally advanced adenocarcinoma of the esophagus or stomach
treated with cisplatin and 5-fluorouracil-based neoadjuvant
chemotherapy. Ann Surg Oncol. 18:2688–2698. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yin M, Yan J, Martinez-Balibrea E, et al:
ERCC1 and ERCC2 polymorphisms predict clinical outcomes of
oxaliplatin-based chemotherapies in gastric and colorectal cancer:
a systemic review and metaanalysis. Clin Cancer Res. 17:1632–1640.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gurubhagavatula S, Liu G, Park S, et al:
XPD and XRCC1 genetic polymorphisms are prognostic factors in
advanced non-small cell lung cancer patients treated with platinum
chemotherapy. J Clin Oncol. 22:2594–2601. 2004. View Article : Google Scholar : PubMed/NCBI
|
